Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors

J. Qiao, H. Wang, T. Kottke, R. M. Diaz, C. Willmon, A. Hudacek, J. Thompson, K. Parato, J. Bell, J. Naik, J. Chester, P. Selby, K. Harrington, A. Melcher, R. G. Vile

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic virotherapy has recently emerged as a promising approach to induce both direct tumor cell killing and local proinflammatory environments within tumors. However, inefficient systemic delivery of oncolytic viruses remains a barrier to use of these agents against metastatic disease that is not directly accessible to the end of a needle. Here we show that the ability of antigen-specific T cells to circulate freely, and to localize to tumors, can be exploited to achieve the systemic delivery of replication-competent, oncolytic vesicular stomatitis virus (VSV). Thus, VSV loaded onto OT-I T cells, specific for the SIINFEKL epitope of the ovalbumin antigen, was efficiently delivered to established B16ova tumors in the lungs of fully immune-competent C57Bl/6 mice leading to significant increases in therapy compared to the use of virus, or T cells, alone. Although OT-I T-cell-mediated delivery of VSV led to viral replication within tumors and direct viral oncolysis, therapy was also dependent upon an intact host immune system. Moreover, VSV loading onto the T cells increased both T-cell activation in vitro and T-cell trafficking in vivo. The combination of adoptive T-cell transfer of antigen-specific T cells, along with oncolytic virotherapy, can, therefore, increase the therapeutic utility of both approaches through multiple mechanisms and should be of direct translational value.

Original languageEnglish (US)
Pages (from-to)604-616
Number of pages13
JournalGene Therapy
Volume15
Issue number8
DOIs
StatePublished - Aug 11 2008

Fingerprint

Vesicular Stomatitis
Cell- and Tissue-Based Therapy
Viruses
T-Lymphocytes
Antigens
Neoplasms
Oncolytic Virotherapy
Oncolytic Viruses
Adoptive Transfer
Ovalbumin
Immunosuppressive Agents
Needles
Epitopes
Immune System
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. / Qiao, J.; Wang, H.; Kottke, T.; Diaz, R. M.; Willmon, C.; Hudacek, A.; Thompson, J.; Parato, K.; Bell, J.; Naik, J.; Chester, J.; Selby, P.; Harrington, K.; Melcher, A.; Vile, R. G.

In: Gene Therapy, Vol. 15, No. 8, 11.08.2008, p. 604-616.

Research output: Contribution to journalArticle

Qiao, J, Wang, H, Kottke, T, Diaz, RM, Willmon, C, Hudacek, A, Thompson, J, Parato, K, Bell, J, Naik, J, Chester, J, Selby, P, Harrington, K, Melcher, A & Vile, RG 2008, 'Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors', Gene Therapy, vol. 15, no. 8, pp. 604-616. https://doi.org/10.1038/sj.gt.3303098
Qiao, J. ; Wang, H. ; Kottke, T. ; Diaz, R. M. ; Willmon, C. ; Hudacek, A. ; Thompson, J. ; Parato, K. ; Bell, J. ; Naik, J. ; Chester, J. ; Selby, P. ; Harrington, K. ; Melcher, A. ; Vile, R. G. / Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. In: Gene Therapy. 2008 ; Vol. 15, No. 8. pp. 604-616.
@article{1ea7472fb9434c20be8627951b73bfc9,
title = "Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors",
abstract = "Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic virotherapy has recently emerged as a promising approach to induce both direct tumor cell killing and local proinflammatory environments within tumors. However, inefficient systemic delivery of oncolytic viruses remains a barrier to use of these agents against metastatic disease that is not directly accessible to the end of a needle. Here we show that the ability of antigen-specific T cells to circulate freely, and to localize to tumors, can be exploited to achieve the systemic delivery of replication-competent, oncolytic vesicular stomatitis virus (VSV). Thus, VSV loaded onto OT-I T cells, specific for the SIINFEKL epitope of the ovalbumin antigen, was efficiently delivered to established B16ova tumors in the lungs of fully immune-competent C57Bl/6 mice leading to significant increases in therapy compared to the use of virus, or T cells, alone. Although OT-I T-cell-mediated delivery of VSV led to viral replication within tumors and direct viral oncolysis, therapy was also dependent upon an intact host immune system. Moreover, VSV loading onto the T cells increased both T-cell activation in vitro and T-cell trafficking in vivo. The combination of adoptive T-cell transfer of antigen-specific T cells, along with oncolytic virotherapy, can, therefore, increase the therapeutic utility of both approaches through multiple mechanisms and should be of direct translational value.",
author = "J. Qiao and H. Wang and T. Kottke and Diaz, {R. M.} and C. Willmon and A. Hudacek and J. Thompson and K. Parato and J. Bell and J. Naik and J. Chester and P. Selby and K. Harrington and A. Melcher and Vile, {R. G.}",
year = "2008",
month = "8",
day = "11",
doi = "10.1038/sj.gt.3303098",
language = "English (US)",
volume = "15",
pages = "604--616",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors

AU - Qiao, J.

AU - Wang, H.

AU - Kottke, T.

AU - Diaz, R. M.

AU - Willmon, C.

AU - Hudacek, A.

AU - Thompson, J.

AU - Parato, K.

AU - Bell, J.

AU - Naik, J.

AU - Chester, J.

AU - Selby, P.

AU - Harrington, K.

AU - Melcher, A.

AU - Vile, R. G.

PY - 2008/8/11

Y1 - 2008/8/11

N2 - Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic virotherapy has recently emerged as a promising approach to induce both direct tumor cell killing and local proinflammatory environments within tumors. However, inefficient systemic delivery of oncolytic viruses remains a barrier to use of these agents against metastatic disease that is not directly accessible to the end of a needle. Here we show that the ability of antigen-specific T cells to circulate freely, and to localize to tumors, can be exploited to achieve the systemic delivery of replication-competent, oncolytic vesicular stomatitis virus (VSV). Thus, VSV loaded onto OT-I T cells, specific for the SIINFEKL epitope of the ovalbumin antigen, was efficiently delivered to established B16ova tumors in the lungs of fully immune-competent C57Bl/6 mice leading to significant increases in therapy compared to the use of virus, or T cells, alone. Although OT-I T-cell-mediated delivery of VSV led to viral replication within tumors and direct viral oncolysis, therapy was also dependent upon an intact host immune system. Moreover, VSV loading onto the T cells increased both T-cell activation in vitro and T-cell trafficking in vivo. The combination of adoptive T-cell transfer of antigen-specific T cells, along with oncolytic virotherapy, can, therefore, increase the therapeutic utility of both approaches through multiple mechanisms and should be of direct translational value.

AB - Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic virotherapy has recently emerged as a promising approach to induce both direct tumor cell killing and local proinflammatory environments within tumors. However, inefficient systemic delivery of oncolytic viruses remains a barrier to use of these agents against metastatic disease that is not directly accessible to the end of a needle. Here we show that the ability of antigen-specific T cells to circulate freely, and to localize to tumors, can be exploited to achieve the systemic delivery of replication-competent, oncolytic vesicular stomatitis virus (VSV). Thus, VSV loaded onto OT-I T cells, specific for the SIINFEKL epitope of the ovalbumin antigen, was efficiently delivered to established B16ova tumors in the lungs of fully immune-competent C57Bl/6 mice leading to significant increases in therapy compared to the use of virus, or T cells, alone. Although OT-I T-cell-mediated delivery of VSV led to viral replication within tumors and direct viral oncolysis, therapy was also dependent upon an intact host immune system. Moreover, VSV loading onto the T cells increased both T-cell activation in vitro and T-cell trafficking in vivo. The combination of adoptive T-cell transfer of antigen-specific T cells, along with oncolytic virotherapy, can, therefore, increase the therapeutic utility of both approaches through multiple mechanisms and should be of direct translational value.

UR - http://www.scopus.com/inward/record.url?scp=43049176729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049176729&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3303098

DO - 10.1038/sj.gt.3303098

M3 - Article

C2 - 18305577

AN - SCOPUS:43049176729

VL - 15

SP - 604

EP - 616

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 8

ER -